Born to survive: how cancer cells resist CAR T cell therapy

J Hematol Oncol. 2021 Nov 22;14(1):199. doi: 10.1186/s13045-021-01209-9.

Abstract

Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant cancer cells. Here, we review the intrinsic resistance mechanisms of cancer cells to CAR T cell therapy and potential strategies to circumvent them.

Keywords: Immunotherapy; Leukemia; Lymphoma; Myeloma; Therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Hematologic Neoplasms / immunology
  • Hematologic Neoplasms / therapy*
  • Humans
  • Immunotherapy, Adoptive* / methods
  • Leukemia / immunology
  • Leukemia / therapy
  • Lymphoma / immunology
  • Lymphoma / therapy
  • Multiple Myeloma / immunology
  • Multiple Myeloma / therapy
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / therapy
  • Tumor Escape